Cargando…
Treatment options for hypertension in high-risk patients
Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients si...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064455/ https://www.ncbi.nlm.nih.gov/pubmed/21468174 http://dx.doi.org/10.2147/VHRM.S11235 |
_version_ | 1782200892613722112 |
---|---|
author | Tsai, Wei-Chuan |
author_facet | Tsai, Wei-Chuan |
author_sort | Tsai, Wei-Chuan |
collection | PubMed |
description | Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials. |
format | Text |
id | pubmed-3064455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-30644552011-04-05 Treatment options for hypertension in high-risk patients Tsai, Wei-Chuan Vasc Health Risk Manag Review Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials. Dove Medical Press 2011 2011-03-09 /pmc/articles/PMC3064455/ /pubmed/21468174 http://dx.doi.org/10.2147/VHRM.S11235 Text en © 2011 Tsai, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Tsai, Wei-Chuan Treatment options for hypertension in high-risk patients |
title | Treatment options for hypertension in high-risk patients |
title_full | Treatment options for hypertension in high-risk patients |
title_fullStr | Treatment options for hypertension in high-risk patients |
title_full_unstemmed | Treatment options for hypertension in high-risk patients |
title_short | Treatment options for hypertension in high-risk patients |
title_sort | treatment options for hypertension in high-risk patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064455/ https://www.ncbi.nlm.nih.gov/pubmed/21468174 http://dx.doi.org/10.2147/VHRM.S11235 |
work_keys_str_mv | AT tsaiweichuan treatmentoptionsforhypertensioninhighriskpatients |